• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Acutus Medical Inc.

    1/21/25 4:25:06 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AFIB alert in real time by email
    S-8 POS 1 dp223624_s8pos-264004.htm FORM S-8 POS

     

    As filed with the Securities and Exchange Commission on January 21, 2025.

     

    Registration Statement No. 333-241143

    Registration Statement No. 333-254799

    Registration Statement No. 333-262467

    Registration Statement No. 333-264004

    Registration Statement No. 333-270811

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    Form S-8 Registration Statement No. 333-241143

    Form S-8 Registration Statement No. 333-254799

    Form S-8 Registration Statement No. 333-262467

    Form S-8 Registration Statement No. 333-264004

    Form S-8 Registration Statement No. 333-270811

     

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Acutus Medical, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware 3841 45-1306615
    (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.)

     

    2210 Faraday Ave., Suite 100

    Carlsbad, CA 92008

    (442) 232-6080

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

     

     

    Acutus Medical, Inc. 2011 Equity Incentive Plan

    Acutus Medical, Inc. 2020 Equity Incentive Plan

    Acutus Medical, Inc. 2020 Employee Stock Purchase Plan

    Acutus Medical, Inc. 2022 Inducement Equity Incentive Plan

    (Full title of the plans)

     

    Takeo Mukai

    Chief Executive Officer & Chief Financial Officer

    Acutus Medical, Inc.

    2210 Faraday Ave., Suite 100

    Carlsbad, CA 92008

    (442) 232-6080

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies of all communications, including all communications sent to the agent for service, should be sent to:

     

    Alan F. Denenberg

    Jason Bassetti

    Davis Polk & Wardwell LLP

    900 Middlefield Road Suite 200

    Redwood City, CA 94063

    (650) 752-2000

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒    

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    EXPLANATORY NOTE – DEREGISTRATION OF SECURITIES

     

    Acutus Medical, Inc., a Delaware corporation (the “Company”), is filing these post-effective amendments (the “Post-Effective Amendments”) to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”), which have been previously filed with the Securities and Exchange Commission (the “SEC”), to deregister any and all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) registered but unsold or otherwise unissued under each such Registration Statement as of the date hereof:

     

    ·Registration Statement on Form S-8 (No. 333-241143), filed with the SEC on August 6, 2020, registering (i) 2,579,156 shares of Common Stock reserved for issuance pursuant to outstanding stock option awards under the Company’s 2011 Equity Incentive Plan (the “2011 Plan”); (ii) 567,509 shares of Common Stock reserved for issuance pursuant to other outstanding equity awards under the 2011 Plan; (iii) 2,193,360 shares of Common Stock available for future issuance under the Company’s 2020 Equity Incentive Plan (the “2020 Plan”); and (iv) 387,063 shares of Common Stock available for future issuance under the Company’s 2020 Employee Stock Purchase Plan (the “2020 ESPP”);

     

    ·Registration Statement on Form S-8 (No. 333-254799), filed with the SEC on March 29, 2021, registering 1,119,657 shares of Common Stock reserved for issuance under the 2020 Plan;

     

    ·Registration Statement on Form S-8 (No. 333-262467), filed with the SEC on February 1, 2022, registering (i) 1,118,288 shares of Common Stock reserved for issuance under the 2020 Plan; and (ii) 258,042 shares of Common Stock reserved for issuance under the 2020 ESPP;

     

    ·Registration Statement on Form S-8 (No. 333-264004), filed with the SEC on March 31, 2022, registering 6,000,000 shares of Common Stock reserved for issuance under the Company’s 2022 Inducement Equity Incentive Plan (the “2022 Plan”); and

     

    ·Registration Statement on Form S-8 (No. 333-270811), filed with the SEC on March 24, 2023, registering (i) 1,142,186 shares of Common Stock reserved for issuance under the 2020 Plan and (ii) 252,042 shares of Common Stock reserved for issuance under the 2020 ESPP.

     

    On January 21, 2025, the Company announced its intention to apply for the voluntary deregistration of its Common Stock from the reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) with the SEC. In connection with the Company’s voluntary decision to deregister, the Company has terminated any and all offerings pursuant to its existing registration statements, including the Registration Statements. Accordingly, this filing is made pursuant to an undertaking made by the Company in Part II of each Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of each offering. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statements as of the date hereof.

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California, on this 21st day of January, 2025.

     

     

    ACUTUS MEDICAL, INC.

       
       
      By: /s/ Takeo Mukai
        Name: Takeo Mukai
        Title: Chief Executive Officer & Chief Financial Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Takeo Mukai his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to the Registration Statements and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, these Post-Effective Amendments have been signed below by the following persons on behalf of the Registrant in the capacities and on the date indicated.

     

    Name   Title   Date
             
    /s/ Takeo Mukai   Chief Executive Officer & Chief Financial Officer   January 21, 2025
    Takeo Mukai   (Principle Executive Officer & Principal Financial and Accounting Officer)    
             
    /s/ Shaden Marzouk   Chair of the Board   January 21, 2025
    Shaden Marzouk, M.D.        
             
    /s/ Andrew ElBardissi   Director   January 21, 2025
    Andrew ElBardissi, M.D.        
             
    /s/ Jason Garland   Director   January 21, 2025
    Jason Garland        
             
    /s/ David Bonita   Director   January 21, 2025
    David Bonita, M.D.        
             
    /s/ Niamh Pellegrini   Director   January 21, 2025
    Niamh Pellegrini        
             
    /s/ John Sheridan   Director   January 21, 2025
    John Sheridan        
             

     

    Get the next $AFIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFIB

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    More analyst ratings